17β-HSD

3-Acetyl-7-Hydroxycoumarin is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). It exhibits significant biological activity, demonstrating 57% inhibition of 17β-HSD1 at a concentration of 6 μM. This compound is valuable for research applications focused on hormone-dependent diseases, including breast cancer and endometriosis.

HSD17B13-IN-94 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in the investigation of liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 provides valuable insights into the underlying mechanisms of these diseases.

S07-2005 (racemic) is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor, exhibiting an IC50 value of 0.13 μM for AKR1C3 and 0.75 μM for AKR1C4. This compound demonstrates significant potential as a chemotherapeutic potentiator, particularly in overcoming resistance mechanisms in cancer treatment. Its selectivity and efficacy make it a valuable tool for research applications focused on cancer biology and drug resistance mechanisms.

HSD17B13-IN-56-d3 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action makes it a significant tool for exploring therapeutic strategies targeting these conditions.

HSD17B13-IN-36 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it valuable for research concerning metabolic disorders and liver health. Its selective inhibition of HSD17B13 may provide insights into therapeutic interventions for liver-related diseases.

HSD17B13-IN-98 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC50 value for estradiol of less than 0.1 μM. This compound is particularly relevant in the investigation of nonalcoholic fatty liver disease, providing valuable insights into the biochemical pathways involved in lipid metabolism and liver function. Its specificity and efficacy make it an essential tool for research focused on metabolic disorders and related therapeutic strategies.

HSD17B13-IN-59 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specific mechanism of action makes it an essential tool in elucidating the role of HSD17B13 in various pathophysiological contexts.

7-Coumaryl triflate is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), demonstrating an IC₅₀ of 360 nM and a Kᵢ of 173 nM. This compound selectively targets 17β-HSD2 while displaying no significant affinity for estrogen receptors ERα or ERβ. 7-Coumaryl triflate is valuable for research focused on hormone-dependent breast cancer and the modulation of estrogen metabolism.

HSD17B13-IN-26 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound exhibits significant activity in the modulation of steroid metabolism and demonstrates potential therapeutic applications in liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Researchers can utilize HSD17B13-IN-26 to further investigate the role of HSD17B13 in liver pathology and associated metabolic disorders.

4'-Hydroxyvalerophenone is a specific inhibitor of 17β-hydroxysteroid dehydrogenase (17β-HSD), exhibiting an IC50 value of 60.52 μM. This compound plays a significant role in steroid metabolism and can be utilized in various research applications related to hormonal regulation and steroid biosynthesis. Its inhibitory effects make it a valuable tool for studies investigating the role of 17β-HSD in physiological and pathological processes.

17β-HSD5 inhibitor 1 is a potent inhibitor of 17β-HSD5, demonstrating an IC50 of 2.9 nM in HEK-293 cells that overexpress human 17β-HSD5. This compound is primarily utilized in research applications related to steroid metabolism and is instrumental in studying the modulation of sex steroid biosynthesis. The selective inhibition of 17β-HSD5 can provide insights into its role in various hormonal disorders and therapeutic interventions.

17β-HSD5 inhibitor 2 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5), demonstrating an IC50 value of 40 nM. This compound is valuable for research into steroid metabolism and androgen biosynthesis, with potential applications in studying conditions related to hormone regulation and prostate cancer. Its inhibitory action enables the exploration of therapeutic strategies targeting 17β-HSD5 in various biological contexts.